According to 36Kr.com, biotechnology company BORAYER has announced the completion of a Series B financing of tens of millions yuan from Bioventure, with participation from WinX Capital as the exclusive financial adviser. Proceeds of this round will be used to promote the clinical research and registration of products and expand sales channels.

Founded in 2017, BORAYER focuses on the research of tissue regeneration and engages in the research and development, and production of wound healing biomaterials. The company provides a series of high-end consumables for clinical medicine, such as rapid hemostasis, wound repair, and guided tissue regeneration.

At present, BORAYER has established a number of technology platforms of polymer biomaterials, including starch and its derivatives, biological polysaccharides, protein compounds, polyurethane compounds, polyethylene glycol (PEG) and its derivatives.

BORAYER's technology of wound repair products and the updated generation of hemostatic materials have been relatively mature. There are more than 10 products under development, most of which are high-value surgical consumables with single market size of more than 2 billion yuan. Several of these products have passed the animal experiments and entered into the registration and application of NMPA in China, CE in the European Economic Area and FDA in the US.

BORAYER has established strategic cooperation with Tsinghua University, Huazhong University of Science and Technology and others, and built academic connections with famous third-grade clinical institutions such as the China-Japan Friendship Hospital, Peking University Third Hospital, and Tsinghua Changgung Hospital. The company has 5,000 square meters of biological materials laboratory, polymer laboratory, cell culture room, animal laboratory, and clean workshop.

Founded in September 2013, Suzhou Industrial Park Bioventure Investment Management Limited ("Bioventure") manages the new bio-industry funds of 540 million yuan. Bioventure invests in life sciences companies such as biotechnology, drug discovery, medical devices and healthcare services companies in the early stages. It provides capital, management, operation, and other post-investment support and services.